Methylene Blue for Vasoplegic Syndrome Postcardiac Surgery

Area of Science:

• Cardiovascular Surgery
• Critical Care Medicine
• Pharmacology

Background:

• Vasoplegia, a refractory hypotension, is a common complication following cardiopulmonary bypass (CPB).
• Traditional vasopressors are often ineffective in managing post-CPB vasoplegia.
• Methylene blue (MB) has emerged as a potential alternative treatment.

Purpose of the Study:

• To evaluate the efficacy of Methylene blue (MB) in treating vasoplegia after cardiopulmonary bypass (CPB).
• To compare hemodynamic recovery, mortality, and morbidity in patients treated with MB versus historical controls.

Main Methods:

• Retrospective observational study matching 28 patients who received MB for vasoplegia post-CPB with historical controls.
• Data collected from 2010-2015 (MB group) and 2004-2009 (control group).
• Primary endpoints included time to vasoplegia improvement (Ti), 30-day mortality, cardiac surgical Intensive Care Unit (CSICU) morbidity, and length of stay (LOS).

Main Results:

• Methylene blue (MB) group showed significantly shorter time to vasoplegia improvement (Ti) and time to vasopressor discontinuation compared to controls (P=0.00 for both).
• 30-day mortality was significantly lower in the MB group (3.6% vs. 21.4%, P=0.04).
• The MB group experienced significantly lower CSICU length of stay (LOS), hospital LOS, and incidence of renal failure (P=0.03, P=0.05, P=0.04 respectively).

Conclusions:

• Methylene blue (MB) administration for vasoplegia post-cardiac surgery is associated with rapid hemodynamic recovery.
• MB treatment led to a reduced need for vasopressors, decreased ICU mortality, and a lower incidence of renal failure.
• The study supports MB as an effective therapeutic option for managing refractory vasoplegia after CPB, resulting in shorter LOS.